Eli Lilly
3,897 hedge funds and large institutions have $583B invested in Eli Lilly in 2025 Q3 according to their latest regulatory filings, with 215 funds opening new positions, 1,793 increasing their positions, 1,456 reducing their positions, and 163 closing their positions.
32% more first-time investments, than exits
New positions opened: 215 | Existing positions closed: 163
23% more repeat investments, than reductions
Existing positions increased: 1,793 | Existing positions reduced: 1,456
0% less funds holding
Funds holding: 3,906 → 3,897 (-9)
4% less capital invested
Capital invested by funds: $610B → $583B (-$26.6B)
8% less call options, than puts
Call options by funds: $12.7B | Put options by funds: $13.9B
1.82% less ownership
Funds ownership: 82.66% → 80.84% (-1.8%)
13% less funds holding in top 10
Funds holding in top 10: 291 → 254 (-37)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$3.22B |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.26B |
| 3 |
Goldman Sachs
New York
|
+$858M |
| 4 |
Amundi
Paris,
France
|
+$718M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$554M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.51B |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$1.98B |
| 3 |
JP Morgan Chase
New York
|
-$1.67B |
| 4 |
Tiger Global Management
New York
|
-$1.18B |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.08B |
LLY Hedge Fund Activity: Q3 2025 in Review
3,897 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q3 2025, worth a combined $583B — down 4.4% from $610B a quarter earlier.
Buyers outnumbered sellers: 215 funds opened new LLY positions and 163 closed out — a net gain of 52 holders — while 1,793 added to existing stakes and 1,456 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $3.22B. The largest seller was T. Rowe Price Associates, cutting an estimated $2.51B.
- 3,897 institutional investors held Eli Lilly (LLY) as of Q3 2025, down from 3,906 in Q2 2025.
- Funds reported $583B of Eli Lilly stock for Q3 2025, down 4.4% quarter-over-quarter.
- 215 funds opened new Eli Lilly positions in Q3 2025 and 163 closed out, a net change of +52 holders.
- The largest Eli Lilly buyer in Q3 2025 was Capital Research Global Investors, an estimated $3.22B added.
- The largest Eli Lilly seller in Q3 2025 was T. Rowe Price Associates, an estimated $2.51B sold.
Based on aggregated 13F filings for Q3 2025.